Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Segment Information

In addition to the significant expense categories included within net loss presented on the Company's Statements of Operations, see below for disaggregated amounts that comprise research and development expenses:

	Year Ended December 31,
	2024		2023		2022
	(in thousands)
External costs:
Third-party CRO, CMO and other third-party clinical trial costs (1)	$	89,400	$	71,294	$	50,175
License upfront payments and milestones		80,000		8,000		2,500
Other research and development costs		8,949		8,465		3,598
Internal costs:
Employee related expenses		49,353		42,762		29,345
Total research and development expenses	$	227,702	$	130,521	$	85,618

(1) Costs incurred under agreements with third-party CROs, CMOs, and other third parties that conduct clinical activities on the Company's behalf.